跳至主要内容
临床试验/IRCT2013020612380N1
IRCT2013020612380N1已完成3 期

Comparing the cost-effectiveness of two alternative bypassing agents (aryoseven & feiba) for patients with hemophilia A complicated by an inhibitor in Iran

Aryogen biopharma co.0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
no limit 至 no limit(—)
性别
All

入选标准

  • patients with severe hemophilia a with high inhibitor titers (greater than or equal to 5 Bethesda) in pilot studies to assess the attitude of coagulation shortcuts are classified.
  • Exclusion criteria: patients who have previously unclassified; patients with coagulation problems, developed liver problems; patients who received coagulation products is over 5 days ago and patients who have bleeding arthritis in the joint within 7 days ago.

排除标准

  • 未提供

研究者

发起方
Aryogen biopharma co.

相似试验